These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 29775786

  • 1. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P, Sartor A, Bassetti M, Scarparo C, Pea F.
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [Abstract] [Full Text] [Related]

  • 2. KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?
    Antochevis LC, Magagnin CM, Nunes AG, Goulart TM, Martins AS, Cayô R, Gales AC, Barth AL, Zavascki AP.
    J Glob Antimicrob Resist; 2018 Dec; 15():173-177. PubMed ID: 30071353
    [Abstract] [Full Text] [Related]

  • 3. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A, Scorzolini L, Cipolla A, Mascellino MT, Cancelli F, Castaldi D, D'Abramo A, D'Agostino C, Russo G, Ciardi MR, Mastroianni CM, Vullo V.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):1981-1984. PubMed ID: 28369424
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S, Renieris G, Machairas N, Sabracos L, Droggiti DI, Misiakos E, Giamarellos-Bourboulis EJ.
    Int J Antimicrob Agents; 2021 Sep 01; 58(3):106384. PubMed ID: 34161789
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC, Dinh A, Nordmann P, Mouton W, Tattevin P, Ghout I, Jayol A, Aimer O, Gatin L, Verdier MC, Saleh-Mghir A, Laurent F.
    J Antimicrob Chemother; 2019 Sep 01; 74(9):2666-2675. PubMed ID: 31263884
    [Abstract] [Full Text] [Related]

  • 7. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B, Sardelić S, Bogdanić M, Zarfel G, Beader N, Šuto S, Krilanović M, Vraneš J.
    Arch Microbiol; 2021 May 01; 203(4):1825-1831. PubMed ID: 33507339
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
    Gaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S.
    J Antimicrob Chemother; 2014 Jul 01; 69(7):1856-65. PubMed ID: 24648503
    [Abstract] [Full Text] [Related]

  • 9. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, Viale P, Re MC, Ambretti S.
    Int J Infect Dis; 2017 Dec 01; 65():1-3. PubMed ID: 28951106
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
    Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Antoniadou A, Study Collaborators.
    Eur J Clin Microbiol Infect Dis; 2019 Jun 01; 38(6):1143-1150. PubMed ID: 30825054
    [Abstract] [Full Text] [Related]

  • 11. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH, Chen CC, Lee MF, Chuang YC, Tang HJ, Yu WL.
    J Microbiol Immunol Infect; 2017 Dec 01; 50(6):931-939. PubMed ID: 28716360
    [Abstract] [Full Text] [Related]

  • 12. Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.
    Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y, Nguyen MH, Clancy CJ, Shields RK.
    Antimicrob Agents Chemother; 2019 Mar 01; 63(3):. PubMed ID: 30617090
    [Abstract] [Full Text] [Related]

  • 13. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I, Antoniadou A, Karaiskos I, Kontopoulou K, Giamarellou H, Souli M.
    Clin Microbiol Infect; 2019 Jun 01; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [Abstract] [Full Text] [Related]

  • 14. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H, Souli M, Study Collaborators.
    BMC Infect Dis; 2019 Feb 15; 19(1):167. PubMed ID: 30770727
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of ComASP™ Colistin (formerly SensiTest™ Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant Klebsiella pneumoniae isolates.
    Galani I, Adamou P, Karaiskos I, Giamarellou H, Souli M.
    J Glob Antimicrob Resist; 2018 Dec 15; 15():123-126. PubMed ID: 30036693
    [Abstract] [Full Text] [Related]

  • 16. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A.
    Int J Antimicrob Agents; 2011 Mar 15; 37(3):244-7. PubMed ID: 21236643
    [Abstract] [Full Text] [Related]

  • 17. Triple combination of meropenem, colistin and tigecycline was bactericidal in a dynamic model despite mere additive interactions in chequerboard assays against carbapenemase-producing Klebsiella pneumoniae isolates.
    Tsala M, Vourli S, Georgiou PC, Pournaras S, Daikos GRL, Mouton JW, Meletiadis J.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):387-394. PubMed ID: 30376071
    [Abstract] [Full Text] [Related]

  • 18. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F, Della Siega P, Cojutti P, Sartor A, Crapis M, Scarparo C, Bassetti M.
    Int J Antimicrob Agents; 2017 Feb 01; 49(2):255-258. PubMed ID: 28012683
    [Abstract] [Full Text] [Related]

  • 19. Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin.
    Tang HJ, Lai CC, Chen CC, Zhang CC, Weng TC, Chiu YH, Toh HS, Chiang SR, Yu WL, Ko WC, Chuang YC.
    J Microbiol Immunol Infect; 2019 Apr 01; 52(2):273-281. PubMed ID: 27133391
    [Abstract] [Full Text] [Related]

  • 20. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P, Sartor A, Righi E, Scarparo C, Bassetti M, Pea F.
    Antimicrob Agents Chemother; 2017 Oct 01; 61(10):. PubMed ID: 28760900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.